Real-World Effectiveness of MOUD and Psychotherapy for Opioid Use Disorder, 2016-2025

A retrospective cohort study of 18,047 U.S. adults aged 18–45 diagnosed with opioid dependence between 2016 and 2025. The data, from the TriNetX Research Network covering 112 health systems, compares remission outcomes across eight treatment cohorts including buprenorphine, methadone, and psychotherapy. The dataset was authored by Nicholas M. Graziane and last updated on 2026-04-28.

Use Cases

• Compare remission hazard ratios for different medication-assisted treatment (MOUD) regimens based on the described cohort definitions.
• Analyze the additive benefit of combining pharmacologic and psychosocial interventions based on the reported adjusted hazard ratios.
• Investigate associations between remission and co-occurring conditions like anxiety or specific prescriptions (e.g., gabapentinoids, benzodiazepines) mentioned in the results.

Strengths

• The study cohort includes 18,047 patient records from 112 U.S. health systems, providing a multi-organizational scale.
• Analysis covers an 8-year time range from 2016 to 2025.
• Results include specific adjusted hazard ratios (aHRs) with 95% confidence intervals for different treatment modalities.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying dataset is unknown, which may limit suitability assessment.
• The data is presented in a 150.8 KB PDF file, which is a tiny dataset and likely contains summary results rather than raw patient-level data.

Provenance

Source

TriNetX Research Network (de-identified electronic health records)

Collection Method

Retrospective cohort study using electronic health records.

Time Range

2016 to 2025

Freshness

Last updated 2026-04-28 05:27:56; freshness should be verified.

Geography

United States (112 health systems)